Patrick Burns News
-
The Internal Revenue Service will review its tax whistle-blower program to improve its backlog and working practices, after the program came under fire from politicians and lawyers.
-
Johnson & Johnson, which has lost judgments of almost $660 million over the marketing of its antipsychotic drug Risperdal, began a trial today in which Texas is seeking damages of more than $1 billion.
-
Bank of New York Mellon Corp. and federal prosecutors are close to settling some claims in a government lawsuit accusing the bank of overcharging customers for foreign-exchange trading, according to a court filing.
-
Johnson & Johnson faces a U.S. government demand to raise its offer by $800 million from an initial proposal to settle a federal civil investigation into marketing of the antipsychotic Risperdal, according to three people familiar with the matter.
-
The Obama administration is targeting waste in government programs and announced a move to squeeze $2.1 billion out of the Medicaid program over the next five years by tracking down improper payments and fraud.
-
Blowing the whistle on drugmakers is becoming a habit for a salesman and a psychiatrist splitting a $45 million award after AstraZeneca Plc settled claims of illegally marketing a schizophrenia drug.
-
Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said.
-
The Senate confirmed Elena Kagan to the U.S. Supreme Court, giving President Barack Obama his second appointment to the high court in two years while leaving its ideological balance unchanged.
-
U.S. Senator Charles Grassley asked 16 drugmakers, including Pfizer Inc. , AstraZeneca Plc and Eli Lilly & Co. , to reveal how they treat whistleblowers who file complaints under the False Claims Act.
-
A U.S. unit of Novartis AG , the Swiss drugmaker, agreed to pay $422.5 million to resolve criminal and civil investigations into the marketing of its epilepsy drug Trileptal.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page